Lp(a) is all the rage, presumably because there’s now a test for it, but its levels are determined by genetics, not lifestyle, and there are no medications currently approved specifically to lower Lp(a) [so what’s the point of testing for something that can’t be fixed?]:
question to Grok: “Are there any medications currently available whose purpose is specifically to lower Lipoprotein(a)?”
Grok: “No, there are currently no medications specifically approved by the FDA or other major regulatory agencies whose primary purpose is to lower Lipoprotein(a) (Lp(a)) levels.
Lp(a) is a genetically determined risk factor for cardiovascular disease, and while some existing treatments can modestly reduce it as a secondary effect, none are indicated or designed explicitly for this goal.
Key Points:
Existing Options with Secondary Lp(a) Effects:PCSK9 inhibitors (e.g., alirocumab/Praluent, evolocumab/Repatha):
These primarily target LDL cholesterol but can lower Lp(a) by 20–30%. They are approved only for high LDL-C or cardiovascular risk reduction, not Lp(a).”
there are no medications currently approved specifically to lower Lp(a) [so what’s the point of testing for something that can’t be fixed?
_____________________________________________
Maybe I won’t get the test after all.